<DOC>
	<DOC>NCT02178098</DOC>
	<brief_summary>This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in patients with hypercholesterolemia and hypertension.</brief_summary>
	<brief_title>Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Mean 24hour ambulatory SBP greater than or equal to 130 mmHg or Mean 24hour ambulatory DBP greater than or equal to 80 mmHg Fasting LDLC between 100 and 220 mg/dL Fasting triglycerides less than 400 mg/dL Body mass index (BMI) between 18 and 45 kg/m2 Known or suspected secondary hypertension or history of malignant hypertension Taking more than two antihypertension medications at the first visit History or current clinically significant cardiovascular disease History or current type 1 diabetes or type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>LDL</keyword>
	<keyword>Cholesterol</keyword>
</DOC>